ArticlePloS one2025
Effects of yeast beta-1,3/1,6-glucans on nutrient digestibility, intestinal functionality, and immune and antioxidant variables in growing dogs submitted to spay or neutering surgery.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From functional ingredients to bioactive compounds: a review of their role in commercial pet food.Veterinary research communications · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to assess the impact of yeast beta-1,3/1,6-glucans (BG) on apparent digestibility coefficients (ADC) of nutrients, intestinal fermentative metabolites, fecal microbiota profile, and immune and antioxidant variables in puppies before and after surgical challenge. Two treatments were evaluated: control, without, and test, with oral supplementation of 65 mg/kg body weight/day of purified BG from Saccharomyces cerevisiae for 120 days. For this, 16 growing Beagle dogs were distributed in a completely randomized design (n = 8/treatment). On day 31, dogs were submitted to spay or neutering surgery. Diet ADC and fecal characteristics analyses were performed on days 55-60. Fecal (days 0, 15, 30, 34, and 60) and blood (days 0, 30, 34, and 60) samples were collected to evaluate intestinal fermentative metabolites, fecal IgA and microbiota, intestinal permeability, and immune and antioxidant variables. On day 80, all dogs were vaccinated for rabies and blood samples were collected on day 120 to determine antibody titers. The supplementation of BG promoted an increase in fecal IgA concentrations on day 15 (P < 0.05) and an increase in fecal concentrations of butyrate (P < 0.05) when day 30 minus day 0 were compared. Dogs of the BG group presented higher fecal concentrations of serotonin (day 15), spermidine (days 15, 30, and 34), and a reduction in tyramine, histamine, and cadaverine on day 60 (P < 0.001). BG consumption promoted an increase in richness and a clear differentiation in the fecal microbiota profile on days 34 and 60 (P < 0.05). BG group also presented an increase in fecal Faecalibacterium, Blautia, and Turicibacter on day 34 (P < 0.05). Reduced glutathione and catalase activities were higher in the BG group (P < 0.05), regardless of the day. In conclusion, the supplementation of BG does not alter the ADC of nutrients, beneficially modulates the intestinal functionality, and stimulates the activity of antioxidant enzymes in growing dogs submitted to a surgical challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.